vs
Orthofix Medical Inc.（OFIX）とRevolve Group, Inc.（RVLV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revolve Group, Inc.の直近四半期売上が大きい（$324.4M vs $219.9M、Orthofix Medical Inc.の約1.5倍）。Revolve Group, Inc.の純利益率が高く（5.7% vs -1.0%、差は6.7%）。Revolve Group, Inc.の前年同期比売上増加率が高い（10.4% vs 2.0%）。Orthofix Medical Inc.の直近四半期フリーキャッシュフローが多い（$16.8M vs $-13.3M）。過去8四半期でRevolve Group, Inc.の売上複合成長率が高い（9.5% vs 8.0%）
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
OFIX vs RVLV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $219.9M | $324.4M |
| 純利益 | $-2.2M | $18.6M |
| 粗利率 | 71.1% | 53.3% |
| 営業利益率 | 0.2% | 6.3% |
| 純利益率 | -1.0% | 5.7% |
| 売上前年比 | 2.0% | 10.4% |
| 純利益前年比 | 92.4% | 50.4% |
| EPS（希薄化後） | $-0.05 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $219.9M | $324.4M | ||
| Q3 25 | $205.6M | $295.6M | ||
| Q2 25 | $203.1M | $309.0M | ||
| Q1 25 | $193.6M | $296.7M | ||
| Q4 24 | $215.7M | $293.7M | ||
| Q3 24 | $196.6M | $283.1M | ||
| Q2 24 | $198.6M | $282.5M | ||
| Q1 24 | $188.6M | $270.6M |
| Q4 25 | $-2.2M | $18.6M | ||
| Q3 25 | $-22.8M | $21.2M | ||
| Q2 25 | $-14.1M | $10.2M | ||
| Q1 25 | $-53.1M | $11.8M | ||
| Q4 24 | $-29.1M | $12.3M | ||
| Q3 24 | $-27.4M | $11.0M | ||
| Q2 24 | $-33.4M | $15.4M | ||
| Q1 24 | $-36.0M | $10.9M |
| Q4 25 | 71.1% | 53.3% | ||
| Q3 25 | 72.2% | 54.6% | ||
| Q2 25 | 68.7% | 54.1% | ||
| Q1 25 | 62.8% | 52.0% | ||
| Q4 24 | 69.0% | 52.5% | ||
| Q3 24 | 68.7% | 51.2% | ||
| Q2 24 | 67.8% | 54.0% | ||
| Q1 24 | 67.5% | 52.3% |
| Q4 25 | 0.2% | 6.3% | ||
| Q3 25 | -8.3% | 7.1% | ||
| Q2 25 | -7.9% | 5.8% | ||
| Q1 25 | -25.2% | 5.0% | ||
| Q4 24 | -5.3% | 3.9% | ||
| Q3 24 | -9.6% | 5.0% | ||
| Q2 24 | -12.5% | 5.8% | ||
| Q1 24 | -15.6% | 3.4% |
| Q4 25 | -1.0% | 5.7% | ||
| Q3 25 | -11.1% | 7.2% | ||
| Q2 25 | -6.9% | 3.3% | ||
| Q1 25 | -27.4% | 4.0% | ||
| Q4 24 | -13.5% | 4.2% | ||
| Q3 24 | -13.9% | 3.9% | ||
| Q2 24 | -16.8% | 5.4% | ||
| Q1 24 | -19.1% | 4.0% |
| Q4 25 | $-0.05 | $0.27 | ||
| Q3 25 | $-0.57 | $0.29 | ||
| Q2 25 | $-0.36 | $0.14 | ||
| Q1 25 | $-1.35 | $0.16 | ||
| Q4 24 | $-0.76 | $0.18 | ||
| Q3 24 | $-0.71 | $0.15 | ||
| Q2 24 | $-0.88 | $0.21 | ||
| Q1 24 | $-0.95 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $82.0M | $292.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $450.0M | $512.5M |
| 総資産 | $850.6M | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $82.0M | $292.3M | ||
| Q3 25 | $62.9M | $315.4M | ||
| Q2 25 | $65.6M | $310.7M | ||
| Q1 25 | $58.0M | $300.8M | ||
| Q4 24 | $83.2M | $256.6M | ||
| Q3 24 | $30.1M | $252.8M | ||
| Q2 24 | $26.4M | $244.7M | ||
| Q1 24 | $27.0M | $273.4M |
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
| Q4 25 | $450.0M | $512.5M | ||
| Q3 25 | $442.5M | $490.2M | ||
| Q2 25 | $458.3M | $468.6M | ||
| Q1 25 | $458.3M | $453.4M | ||
| Q4 24 | $503.1M | $437.8M | ||
| Q3 24 | $525.9M | $420.8M | ||
| Q2 24 | $546.0M | $405.8M | ||
| Q1 24 | $570.3M | $389.9M |
| Q4 25 | $850.6M | $765.0M | ||
| Q3 25 | $832.6M | $751.3M | ||
| Q2 25 | $837.2M | $722.9M | ||
| Q1 25 | $823.1M | $713.9M | ||
| Q4 24 | $893.3M | $665.5M | ||
| Q3 24 | $867.9M | $670.9M | ||
| Q2 24 | $882.0M | $657.8M | ||
| Q1 24 | $906.0M | $650.0M |
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $27.7M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $16.8M | $-13.3M |
| FCFマージンFCF / 売上 | 7.6% | -4.1% |
| 設備投資強度設備投資 / 売上 | 4.9% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | — | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $-1.3M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $27.7M | $-10.2M | ||
| Q3 25 | $12.4M | $11.8M | ||
| Q2 25 | $11.6M | $12.6M | ||
| Q1 25 | $-18.4M | $45.1M | ||
| Q4 24 | $23.7M | $3.9M | ||
| Q3 24 | $11.7M | $9.1M | ||
| Q2 24 | $9.0M | $-24.7M | ||
| Q1 24 | $-18.6M | $38.4M |
| Q4 25 | $16.8M | $-13.3M | ||
| Q3 25 | $2.5M | $7.5M | ||
| Q2 25 | $4.5M | $10.4M | ||
| Q1 25 | $-25.1M | $43.4M | ||
| Q4 24 | $15.2M | $2.1M | ||
| Q3 24 | $6.3M | $8.0M | ||
| Q2 24 | $-360.0K | $-25.7M | ||
| Q1 24 | $-29.1M | $36.7M |
| Q4 25 | 7.6% | -4.1% | ||
| Q3 25 | 1.2% | 2.5% | ||
| Q2 25 | 2.2% | 3.4% | ||
| Q1 25 | -13.0% | 14.6% | ||
| Q4 24 | 7.0% | 0.7% | ||
| Q3 24 | 3.2% | 2.8% | ||
| Q2 24 | -0.2% | -9.1% | ||
| Q1 24 | -15.4% | 13.5% |
| Q4 25 | 4.9% | 1.0% | ||
| Q3 25 | 4.8% | 1.5% | ||
| Q2 25 | 3.5% | 0.7% | ||
| Q1 25 | 3.5% | 0.6% | ||
| Q4 24 | 4.0% | 0.6% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 4.7% | 0.4% | ||
| Q1 24 | 5.6% | 0.6% |
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | — | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
